Drug Information

Drug General Information
Drug ID
D02FPF
Former ID
DNC008339
Drug Name
JUGLONE
Drug Type
Small molecular drug
Indication Discovery agent Investigative [529353]
Formula
C10H6O3
Canonical SMILES
C1=CC2=C(C(=O)C=CC2=O)C(=C1)O
InChI
1S/C10H6O3/c11-7-4-5-9(13)10-6(7)2-1-3-8(10)12/h1-5,12H
InChIKey
KQPYUDDGWXQXHS-UHFFFAOYSA-N
PubChem Compound ID
3806
Target and Pathway
Target(s) Dual specificity protein phosphatase 1 Target Info Inhibitor [529817]
Arachidonate 5-lipoxygenase Target Info Inhibitor [534507]
M-phase inducer phosphatase 2 Target Info Inhibitor [529817]
Indoleamine 2,3-dioxygenase Target Info Inhibitor [529353]
BioCyc Pathway Aspirin-triggered lipoxin biosynthesis
Resolvin D biosynthesis
Leukotriene biosynthesis
Lipoxin biosynthesis
Aspirin triggered resolvin D biosynthesis
Aspirin triggered resolvin E biosynthesisPWY66-401:Superpathway of tryptophan utilization
Tryptophan degradation
L-kynurenine degradation
Tryptophan degradation to 2-amino-3-carboxymuconate semialdehyde
NAD de novo biosynthesis
KEGG Pathway MAPK signaling pathway
Serotonergic synapsehsa00590:Arachidonic acid metabolism
Metabolic pathways
Serotonergic synapse
Ovarian steroidogenesis
Toxoplasmosishsa04010:MAPK signaling pathway
Cell cycle
Progesterone-mediated oocyte maturation
MicroRNAs in cancerhsa00380:Tryptophan metabolism
African trypanosomiasis
NetPath Pathway FSH Signaling Pathway
IL2 Signaling Pathway
EGFR1 Signaling Pathway
Wnt Signaling Pathway
TCR Signaling PathwayNetPath_16:IL4 Signaling PathwayNetPath_14:IL2 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
Wnt Signaling PathwayNetPath_24:TSLP Signaling Pathway
IL5 Signaling Pathway
Pathway Interaction Database Fc-epsilon receptor I signaling in mast cells
Regulation of p38-alpha and p38-beta
Direct p53 effectors
ErbB1 downstream signaling
ATF-2 transcription factor network
AP-1 transcription factor networkplk1_pathway:PLK1 signaling events
FOXM1 transcription factor network
p38 signaling mediated by MAPKAP kinases
Aurora A signaling
PathWhiz Pathway Arachidonic Acid MetabolismPW000163:Tryptophan Metabolism
Reactome RAF-independent MAPK1/3 activation
Negative regulation of MAPK pathwayR-HSA-157881:Cyclin B2 mediated events
Cyclin A/B1 associated events during G2/M transition
Cyclin A:Cdk2-associated events at S phase entryR-HSA-71240:Tryptophan catabolism
WikiPathways MAPK Signaling PathwayWP2877:Vitamin D Receptor Pathway
Arachidonic acid metabolism
Eicosanoid Synthesis
Selenium Micronutrient NetworkWP615:Senescence and Autophagy in Cancer
MAPK Signaling Pathway
Retinoblastoma (RB) in Cancer
Prostate Cancer
Integrated Breast Cancer Pathway
Integrated Cancer pathway
Mitotic G2-G2/M phases
Cell CycleWP465:Tryptophan metabolism
Metabolism of amino acids and derivatives
References
Ref 529353J Med Chem. 2008 Mar 27;51(6):1706-18. Epub 2008 Mar 5.Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.
Ref 529353J Med Chem. 2008 Mar 27;51(6):1706-18. Epub 2008 Mar 5.Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.
Ref 529817Bioorg Med Chem. 2009 Mar 15;17(6):2276-81. Epub 2008 Nov 8.Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases.
Ref 534507J Med Chem. 1997 Nov 7;40(23):3773-80.Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.